This week saw both Regenxbio and Solid Bio report new data with their gene therapy candidates for Duchenne muscular dystrophy ...

Hans Schambe joins BOOST Pharma – a clinical-stage biopharmaceutical company developing novel off-the-shelf cell therapies for rare paediatric skeletal diseases – from Galecto Inc., where as president ...

Hospitals in England have been urged to block the implementation of software developed by controversial tech firm Palantir by a coalition of patient, healthcare, worker, trade union, and consumer ...

Bristol Myers Squibb has brought one drug in the class to market – Opdualag, which combined LAG-3 drug relatlimab with PD-1 inhibitor nivolumab – but the company has subsequently been plagued by a ...

Many Americans are forced to make difficult trade-offs with living expenses and delay life events like retirement to afford health, says a new poll. The Gallup/West Health survey (PDF) of around ...

The consequences of the US-Israel war in Iran have spilled over into the medtech sector, with a cyberattack launched against prominent US company Stryker. An Iranian hacker group has claimed ...

Chip giant NVIDIA has agreed a $2 billion partnership with AI cloud provider Nebius, a supplier to the life sciences industry and other sectors, focusing on the design and development of 'AI factories ...

Built on groundbreaking research from Israel ’s Weizmann Institute of Science, Promise Bio developed the first cloud-based platform for broad epiproteomics, helping researchers uncover disease ...

Eisai has launched a campaign to raise awareness of sleep disorders in Japan, via a partnership with smartphone app Pokémon ...

Evotec has announced the next phase of its company overhaul, dubbed Horizon, that will see 800 people lose their jobs in a bid to cut €75 million in costs by the end of 2027. The layoffs follow around ...

Moderna has agreed to settle litigation with Arbutus Biopharma and Roivant's Genevant that claimed its blockbuster COVID-19 vaccine infringed patents, with an upfront payment of $950 million. Arbutus ...

In a move that will delight Novo Nordisk and Eli Lilly, the FDA has sent warning letters to 30 telehealth companies, accusing them of illegally marketing compounded GLP-1 agonist formulations. The ...